CN116349734A - 一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法 - Google Patents
一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法 Download PDFInfo
- Publication number
- CN116349734A CN116349734A CN202310222688.7A CN202310222688A CN116349734A CN 116349734 A CN116349734 A CN 116349734A CN 202310222688 A CN202310222688 A CN 202310222688A CN 116349734 A CN116349734 A CN 116349734A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- milk
- whey protein
- infant formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 152
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 70
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 42
- 230000029087 digestion Effects 0.000 title claims abstract description 39
- 230000001737 promoting effect Effects 0.000 title claims abstract description 35
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 28
- 235000013336 milk Nutrition 0.000 title claims abstract description 18
- 239000008267 milk Substances 0.000 title claims abstract description 18
- 210000004080 milk Anatomy 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 20
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 77
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 77
- 235000021119 whey protein Nutrition 0.000 claims abstract description 66
- 239000012528 membrane Substances 0.000 claims abstract description 32
- 108010071421 milk fat globule Proteins 0.000 claims abstract description 32
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 30
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 30
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 25
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 23
- 239000011707 mineral Substances 0.000 claims abstract description 23
- 229940088594 vitamin Drugs 0.000 claims abstract description 23
- 229930003231 vitamin Natural products 0.000 claims abstract description 23
- 235000013343 vitamin Nutrition 0.000 claims abstract description 23
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- 235000010755 mineral Nutrition 0.000 claims abstract description 22
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000005018 casein Substances 0.000 claims abstract description 20
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000021240 caseins Nutrition 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 15
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 15
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 15
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 15
- 235000019197 fats Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 230000001954 sterilising effect Effects 0.000 claims abstract description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 13
- 239000008101 lactose Substances 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 13
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 12
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 12
- 239000001656 lutein Substances 0.000 claims abstract description 12
- 229960005375 lutein Drugs 0.000 claims abstract description 12
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 12
- 235000012680 lutein Nutrition 0.000 claims abstract description 12
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 12
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 12
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 12
- 239000005862 Whey Substances 0.000 claims abstract description 11
- 229960003080 taurine Drugs 0.000 claims abstract description 11
- 235000020247 cow milk Nutrition 0.000 claims abstract description 10
- 239000011265 semifinished product Substances 0.000 claims abstract description 10
- 235000020185 raw untreated milk Nutrition 0.000 claims abstract description 9
- 238000007580 dry-mixing Methods 0.000 claims abstract description 7
- 210000000936 intestine Anatomy 0.000 claims abstract description 6
- 238000001694 spray drying Methods 0.000 claims abstract description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 11
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 10
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 5
- 235000019743 Choline chloride Nutrition 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- 235000000638 D-biotin Nutrition 0.000 claims description 5
- 239000011665 D-biotin Substances 0.000 claims description 5
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 5
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 229960003563 calcium carbonate Drugs 0.000 claims description 5
- 235000010216 calcium carbonate Nutrition 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 229960003178 choline chloride Drugs 0.000 claims description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 5
- 229960000355 copper sulfate Drugs 0.000 claims description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 5
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 5
- 239000011666 cyanocobalamin Substances 0.000 claims description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 5
- 229960001781 ferrous sulfate Drugs 0.000 claims description 5
- 239000011790 ferrous sulphate Substances 0.000 claims description 5
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 5
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 229960003390 magnesium sulfate Drugs 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 229940099596 manganese sulfate Drugs 0.000 claims description 5
- 239000011702 manganese sulphate Substances 0.000 claims description 5
- 235000007079 manganese sulphate Nutrition 0.000 claims description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- 229960002816 potassium chloride Drugs 0.000 claims description 5
- 239000001508 potassium citrate Substances 0.000 claims description 5
- 229960002635 potassium citrate Drugs 0.000 claims description 5
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 5
- 235000011082 potassium citrates Nutrition 0.000 claims description 5
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 claims description 5
- 239000001230 potassium iodate Substances 0.000 claims description 5
- 235000006666 potassium iodate Nutrition 0.000 claims description 5
- 229940093930 potassium iodate Drugs 0.000 claims description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 5
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 5
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 5
- 229960000342 retinol acetate Drugs 0.000 claims description 5
- 235000019173 retinyl acetate Nutrition 0.000 claims description 5
- 239000011770 retinyl acetate Substances 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 229960002668 sodium chloride Drugs 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 239000011781 sodium selenite Substances 0.000 claims description 5
- 235000015921 sodium selenite Nutrition 0.000 claims description 5
- 229960001471 sodium selenite Drugs 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 5
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 5
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 5
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 5
- 235000005282 vitamin D3 Nutrition 0.000 claims description 5
- 239000011647 vitamin D3 Substances 0.000 claims description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 5
- 229940021056 vitamin d3 Drugs 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 4
- 239000002211 L-ascorbic acid Substances 0.000 claims description 4
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 4
- 229960002104 cyanocobalamin Drugs 0.000 claims description 4
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- -1 phytomenaquinone Chemical compound 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 230000035764 nutrition Effects 0.000 abstract description 7
- 210000002784 stomach Anatomy 0.000 abstract description 5
- 210000004379 membrane Anatomy 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 24
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 12
- 235000020256 human milk Nutrition 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000004251 human milk Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 235000021314 Palmitic acid Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 5
- 229940107187 fructooligosaccharide Drugs 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000021052 average daily weight gain Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本申请涉及配方奶粉技术领域,具体公开了一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法,所述配方奶粉包括原料a2‑β酪蛋白型生牛乳、脱盐乳清粉、OPO结构脂、水解乳清蛋白粉、富含乳脂肪球膜的浓缩乳清蛋白粉、乳糖、膳食纤维、矿物质、维生素、花生四烯酸粉末、二十二碳六烯酸粉末、牛磺酸、动物双歧杆菌Bb‑12和叶黄素;上述配方奶粉营养配比合理,能为宝宝提供全方位、均衡的关键营养,不给宝宝肠胃增加负担;所述制备方法,包括将a2‑β酪蛋白型生牛乳、OPO结构脂、膳食纤维、矿物质和维生素混料后杀菌浓缩、喷雾干燥得半成品;将半成品与剩余原料干混即得;本申请制备方法有效保护了配方奶粉中的有效成分。
Description
技术领域
本申请涉及配方奶粉技术领域,更具体地说,它涉及一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法。
背景技术
众所周知,健康的母乳永远是喂养婴儿最佳的选择。初生婴儿肠道处于无菌状态,母乳中含有大量特殊结构的双歧因子低聚多糖,有利于双歧杆菌在婴儿肠道的生长繁殖,还含有活性双歧杆菌。所以母乳喂养的婴儿,消化吸收好,排泄正常,免疫系统发育更为完善。但是,在母乳不足或者因各种原因不能母乳喂养的情况下,婴儿配方奶粉成为可供选择的最佳食品之一。
相关技术中,婴幼儿配方奶粉大都是以母乳为黄金标准,蛋白质是母乳中最为重要的营养物质之一,其含量、组成及比例是决定母乳质量的重要指标,也是迄今为止人们研究最多的内容。但是,目前的配方乳粉中含有的蛋白质多为大分子蛋白质,对于婴幼儿尤其是处于生命初期的婴幼儿而言,其消化吸收能力有限,高分子的蛋白质(与小分子的多肽或者氨基酸相比)给肠道带来了很大的消化吸收负担,且诸多蛋白最终会因为无法消化而流失,且容易造成肠道菌群的失衡,产生不良后果。
另外,母乳脂质是人类母乳中仅次于乳糖的第二大成分,是婴儿生长发育重要营养物质,可以满足4055%的能量需求。在母乳中,sn-2位棕榈酸占比例高达70%,而普通配方奶粉只有10%。普通配方奶粉中棕榈酸通常在sn-1或sn-3位酯化,因此在释放时吸收不太好,在婴儿中通常形成钙皂,不利于脂肪酸的吸收,还会降低钙的吸收、同时还会增加宝宝大便硬度,导致便秘。基于上述陈述,本申请提供了一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法。
发明内容
为了解决现有配方奶粉易造成肠道菌群失衡,营养成分不易被婴儿消化吸收等问题,本申请提供了一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法。
第一方面,本申请提供了一种促进消化吸收的肠道型婴儿配方奶粉,采用如下的技术方案:
一种促进消化吸收的肠道型婴儿配方奶粉,包括以下重量份的原料:a2-β酪蛋白型生牛乳1500-2100份、脱盐乳清粉300-500份、OPO结构脂100-150份、水解乳清蛋白粉40-70份、富含乳脂肪球膜的浓缩乳清蛋白粉40-70份、乳糖40-60份、膳食纤维40-60份、矿物质20-30份、维生素12-18份、花生四烯酸粉末5-10份、二十二碳六烯酸粉末2-5份、牛磺酸0.1-1份、动物双歧杆菌Bb-12 0.1-1份、叶黄素0.01-0.1份。
优选的,所述促进消化吸收的肠道型婴儿配方奶粉,包括以下重量份的原料:a2-β酪蛋白型生牛乳1600-2000份、脱盐乳清粉350-450份、OPO结构脂110-140份、水解乳清蛋白粉50-60份、富含乳脂肪球膜的浓缩乳清蛋白粉50-60份、乳糖45-55份、膳食纤维45-55份、矿物质22-28份、维生素13-17份、花生四烯酸粉末6-9份、二十二碳六烯酸粉末3-4份、牛磺酸0.3-0.8份、动物双歧杆菌Bb-12 0.3-0.8份、叶黄素0.03-0.08份。
优选的,所述促进消化吸收的肠道型婴儿配方奶粉,包括以下重量份的原料:a2-β酪蛋白型生牛乳1800份、脱盐乳清粉400份、OPO结构脂125份、乳水解乳清蛋白粉55份、富含乳脂肪球膜的浓缩乳清蛋白粉55份、乳糖50份、膳食纤维50份、矿物质25份、维生素15份、花生四烯酸粉末7.5份、二十二碳六烯酸粉末3.5份、牛磺酸0.5份、动物双歧杆菌Bb-12 0.5份、叶黄素0.05份。
通过采用上述技术方案,本申请选用a2-β酪蛋白型生牛乳做基料,配合添加脱盐乳清粉、OPO结构脂、水解乳清蛋白粉、富含乳脂肪球膜的浓缩乳清蛋白粉、乳糖、膳食纤维、矿物质、维生素、花生四烯酸粉末、二十二碳六烯酸粉末、牛磺酸、动物双歧杆菌Bb-12和叶黄素,制得所需婴儿配方奶粉;
a2-β酪蛋白型生牛乳富含免疫球蛋白、乳铁蛋白、生长因子及蛋白质,能够补充生长发育必须的蛋白质和钙质,同时增强体质,提高免疫力;其中添加的a2-β酪蛋白可以促进人体的钙、铁、锌的吸收,可以持续向血液输送氨基酸,能够促进儿童的健康生育发展;
脱盐乳清粉用于调整配方奶粉中蛋白质比例,让配方奶粉的营养供应和口感更接近母乳水平,促进胃肠的消化吸收,满足婴幼儿的生长发育要求;
OPO结构脂是一种模拟母乳脂质的结构化脂肪,通过酶促酯交换技术,来提高配方奶粉中sn-2位棕榈酸的比例,在配方奶粉中添加1,3-二油酸-2-棕榈酸甘油三酯可以使sn-2位棕榈酸达到40%以上,从而更容易被消化吸收;
水解乳清蛋白能够进入宝宝消化道时呈现一种“预消化”的短肽形式,更容易被机体吸收与利用,减少宝宝的胃肠道负担;
富含乳脂肪球膜的浓缩乳清蛋白粉中的乳脂肪球膜结构能够与肠道上皮细胞结合,抑制肠内细菌发生,起到保护肠粘膜、修复受损细胞和抗感染等功效;
乳糖的添加,能够调整配方奶粉的口感,提供婴儿生长发育所需的能量,保持体内水分平衡,提供大脑及重要器官构成有关的半乳糖,促进智力发育,同时乳糖被小肠中被乳酸杆菌等有益菌群利用,能够生成乳酸,对婴儿肠胃起到调整保护作用,抑制肠道腐败菌的生长,促进营养元素的吸收;
往配方奶粉中添加膳食纤维,能够提高宝宝大便当中的水分,从而使大便保持软化,另外大便在吸收肠壁水分的同时,也会刺激肠道加速蠕动,从而帮助预防和改善便秘症状;膳食纤维的摄入还可以改善肠道消化吸收能力,能够促进钙、镁、铁等矿物质在宝宝肠道当中的吸收率,进而促进宝宝的生长发育;
在配方奶粉中添加矿物质和维生素,能够起到促进新陈代谢,维持集体平衡,维持心脏正常功能,增强机体免疫力等作用。
花生四烯酸粉末中含有总质量10%的花生四烯酸,二十二碳六烯酸粉末中含有总质量10%的二十二碳六烯酸;花生四烯酸粉末和二十二碳六烯酸粉末分别由乳清蛋白粉包埋获得;在配方奶粉中添加花生四烯酸和二十二碳六烯酸能够提升婴儿智力发育指数,提升视力敏锐度,促进婴儿脑部及视力的发育,通过控制两者的添加量,还能够调节婴儿肠道菌群结构;
牛磺酸有助于促进婴幼儿脑组织和智力发育,提高神经传导和视觉机能,同时还能改善内分泌状态,增强免疫力;
在配方奶粉中适当添加动物双歧杆菌Bb-12,能够有效预防婴儿感染、腹泻风险,增加对营养物质的吸收能力;
叶黄素具有滤过蓝光、保护视网膜、抗氧化、预防血管硬化等作用,在配方奶粉中适当添加叶黄素能够进一步提升婴儿视觉机能和视力敏锐度;
本申请配方奶粉营养配比合理,能为宝宝提供全方位、均衡的关键营养,易消化吸收,不给宝宝肠胃增加负担,有利肠道益生菌发生发展,有利于婴幼儿智力、视力的生长发育。
优选的,所述水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的质量比为1-1.5:1。
通过采用上述技术方案,本申请乳清蛋白粉选用水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的混合物,通过控制两者的质量比在上述范围内,两者协同增效,能够在优化配方奶粉中蛋白质组成的同时,进一步起到促进消化吸收,减少肠胃负担,降低腹泻的功效。
优选的,所述膳食纤维包括质量比1.5-4:1的低聚半乳糖和低聚果糖。
通过采用上述技术方案,配方奶粉中的膳食纤维选用低聚半乳糖和低聚果糖的混合物,且控制两者的质量比为1.5-4:1,尤其是2:1时,可以显著预防和改善便秘症状;且进一步提高了肠道消化能力和营养吸收能力。
优选的,所述矿物质包括磷酸三钙、柠檬酸钾、氯化钠、氯化钾、硫酸镁、碳酸钙、碘酸钾、硫酸铜、硫酸亚铁、硫酸锌、亚硒酸钠和硫酸锰;
所述磷酸三钙、柠檬酸钾、氯化钠、氯化钾、硫酸镁、碳酸钙、碘酸钾、硫酸铜、硫酸亚铁、硫酸锌、亚硒酸钠和硫酸锰的质量比为12-14:9-13:16-20:18-22:4.5-7.5:9-11:3.2-4.6:0.01-0.05:1-3:7.2-7.8:1.5-2.5:0.1-0.3。
优选的,所述矿物质包括质量比为13:11:18:20:6:10:3.9:0.03:2:7.5:2:0.2的磷酸三钙、柠檬酸钾、氯化钠、氯化钾、硫酸镁、碳酸钙、碘酸钾、硫酸铜、硫酸亚铁、硫酸锌、亚硒酸钠和硫酸锰;
通过采用上述技术方案,本申请通过控制矿物质的选用及组成配比,实现维持机体电解质和液体平衡,维持心脏正常功能,促进新陈代谢;在满足婴儿生长需求的同时,还能够改善配方奶粉的口感,促进消化吸收。
优选的,所述维生素包括L-抗坏血酸、氯化胆碱、肌醇、DL-α-醋酸生育酚、盐酸吡哆醇、胆钙化醇、醋酸视黄酯、烟酰胺、D-泛酸钙、叶酸、D-生物素、植物甲萘醌、核黄素、盐酸硫胺素和氰钴胺;
所述L-抗坏血酸、氯化胆碱、肌醇、DL-α-醋酸生育酚、盐酸吡哆醇、胆钙化醇、醋酸视黄酯、烟酰胺、D-泛酸钙、叶酸、D-生物素、植物甲萘醌、核黄素、盐酸硫胺素和氰钴胺的质量比为120-140:44-46:28-35:17-19:13-15:8-10:6-9:4-7:4-5:3-4:4-7:0.1-0.3:0.1-0.2:0.1-0.12:0.01-0.1。
优选的,所述维生素包括质量比为130:45:32:18:14:9:7.5:5.5:4.5:3.5:5.5:0.2:0.15:0.11:0.05的L-抗坏血酸、氯化胆碱、肌醇、DL-α-醋酸生育酚、盐酸吡哆醇、胆钙化醇、醋酸视黄酯、烟酰胺、D-泛酸钙、叶酸、D-生物素、植物甲萘醌、核黄素、盐酸硫胺素和氰钴胺。
通过采用上述技术方案,本申请通过控制维生素的选用及组成配比,能够维持机体正常生长,促进发育和细胞再生,促进视觉、神经、感染免疫系统健全;增进食欲、帮助消化,促进新陈代谢等。
第二方面,本申请提供了一种促进消化吸收的肠道型婴儿配方奶粉的制备方法,采用如下的技术方案:
一种促进消化吸收的肠道型婴儿配方奶粉的制备方法,包括以下制备步骤:
S1、验收原辅料后,将a2-β酪蛋白型生牛乳进行净乳及巴氏杀菌;
S2、以a2-β酪蛋白型生牛乳为基料,将OPO结构脂、膳食纤维加入到a2-β酪蛋白型生牛乳中,加入矿物质进行湿混配料,均质后,加入维生素配料,杀菌浓缩、喷雾干燥、冷却获得半成品;
S3、将剩余原辅料进行杀菌后与步骤S2中的半成品进行干混,混合均匀后包装即得所需婴儿配方奶粉。
优选的,所述步骤S2中矿物质和维生素加入前需分别进行预溶解,溶解水温均为40-45℃,溶解时间为1-3min。
优选的,所述步骤S2中杀菌浓缩条件为:杀菌温度为86-95℃,流量为7-7.5吨/h。
优选的,所述步骤S2中喷雾干燥条件为:进风温度为150-180℃,排风温度为80-95℃,高压泵压力为12-20MPa,出粉水份≤3.5%。
优选的,所述步骤S2中冷却条件为:一段进风温度为20-70℃,二、三段进风温度为15-25℃,出粉温度≤30℃,进行流化床冷却。
优选的,所述步骤S3中杀菌的条件为:杀菌隧道的紫外线强度为100-120μW/cm2,隧道杀菌时间为100-120s。
优选的,所述步骤S3中干混的条件为:混合转速为42r/min,混合时间为300s。
通过采用上述技术方案,本申请通过控制原料混合顺序,采用湿混配料获得半成品后再干混制得所需配方奶粉;本申请制备方法简单,通过严格控制制备参数,有效的保护了配方奶粉中的有效成分。
综上所述,本申请具有以下有益效果:
1、本申请配方奶粉营养配比合理,能为宝宝提供全方位、均衡的关键营养,易消化吸收,不给宝宝肠胃增加负担,有利肠道益生菌发生发展,有利于婴幼儿智力、视力的生长发育。
2、本申请采用添加OPO结构脂,可以使配方奶粉中的脂肪酸结构更加贴近母乳,进一步提高配方奶粉中sn-2位棕榈酸的比例,帮助宝宝消化吸收,促进宝宝生长发育。
3、本申请选用水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉两者复配添加,能够在优化配方奶粉中蛋白质组成的同时,进一步起到促进消化吸收,减少肠胃负担,降低腹泻的功效。
4、本申请膳食纤维选用低聚半乳糖和低聚果糖的混合物,且控制两者的质量比为1.5-4:1,尤其是3:1时,可以显著预防和改善便秘症状;且进一步提高了肠道消化能力和营养吸收能力。
5、本申请通过控制原料混合顺序,采用湿混配料获得半成品后再干混制得所需配方奶粉;本申请制备方法简单,通过严格控制制备参数,有效的保护了配方奶粉中的有效成分。
具体实施方式
实施例1-12提供了一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法,以下以实施例1为例进行说明。
实施例1
一种促进消化吸收的肠道型婴儿配方奶粉,包括以下原料:a2-β酪蛋白型生牛乳1500Kg、D90脱盐乳清粉300Kg、OPO结构脂100Kg、水解乳清蛋白粉40kg、富含乳脂肪球膜的浓缩乳清蛋白粉40kg、乳糖40Kg、膳食纤维40Kg、矿物质20Kg、维生素12Kg、花生四烯酸粉末5Kg、二十二碳六烯酸粉末2Kg、牛磺酸0.1Kg、动物双歧杆菌Bb-12 0.1Kg、叶黄素0.01Kg;
其中,膳食纤维包括质量比3:1的低聚半乳糖和低聚果糖;
矿物质包括质量比为13:11:18:20:6:10:3.9:0.03:2:7.5:2:0.2的磷酸三钙、柠檬酸钾、氯化钠、氯化钾、硫酸镁、碳酸钙、碘酸钾、硫酸铜、硫酸亚铁、硫酸锌、亚硒酸钠和硫酸锰;
维生素包括130:45:32:18:14:9:7.5:5.5:4.5:3.5:5.5:0.2:0.15:0.11:0.05的L-抗坏血酸、氯化胆碱、肌醇、DL-α-醋酸生育酚、盐酸吡哆醇、胆钙化醇、醋酸视黄酯、烟酰胺、D-泛酸钙、叶酸、D-生物素、植物甲萘醌、核黄素、盐酸硫胺素和氰钴胺;
动物双歧杆菌Bb-12的含菌量为1×1010CFU/g。
一种促进消化吸收的肠道型婴儿配方奶粉的制备方法,包括以下制备步骤:
S1、验收原辅料后,将a2-β酪蛋白型生牛乳进行净乳及巴氏杀菌,控制巴氏杀菌温度为78℃,杀菌时间为16s;
S2、预先将矿物质和维生素分别进行溶解,溶解水温均为40℃,溶解时间为3min;
以a2-β酪蛋白型生牛乳为基料,在配料罐中加入OPO结构脂、膳食纤维,以80r/min的转速预混10min,加入预先溶解的矿物质继续混合3min,然后在温度为50℃,压力为12MPa的条件下均质处理20s,加入预先溶解的维生素搅拌混合均匀后,在杀菌温度为86℃,流量为7吨/h的条件下进行杀菌浓缩;控制进风温度为150℃,排风温度为80℃,高压泵压力为12MPa,出粉水份为3.5%,进行喷雾干燥;控制一段进风温度为20℃,二、三段进风温度为15℃,出粉温度为30℃,进行流化床冷却得半成品;
S3、利用紫外线隧道杀菌机将剩余原辅料脱盐乳清粉、乳清蛋白粉、乳糖、花生四烯酸粉末、二十二碳六烯酸粉末、牛磺酸、动物双歧杆菌Bb-12和叶黄素进行杀菌,控制杀菌隧道的紫外线强度为100μW/cm2,隧道杀菌时间为120s;完成杀菌后与步骤S2中的半成品进行干混,控制混合转速为42r/min,混合时间为300s,混合均匀后包装即得所需婴儿配方奶粉。
实施例2-5,同实施例1,区别仅在于,配方奶粉的原料用量不同,具体见表1。
表1:
实施例6-7,同实施例3,区别仅在于,制备方法参数不同,具体见表2。
表2:
实施例8
实施例8,同实施例6,不同之处仅在于,控制水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的总添加量不变,水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的质量比为1.2:1,即水解乳清蛋白粉60Kg、富含乳脂肪球膜的浓缩乳清蛋白粉50Kg。
实施例9
实施例9,同实施例6,不同之处仅在于,控制水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的总添加量不变,水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的质量比为1.5:1,即水解乳清蛋白粉66Kg、富含乳脂肪球膜的浓缩乳清蛋白粉44Kg。
实施例10
实施例10,同实施例6,不同之处仅在于,膳食纤维包括质量比1.5:1的低聚半乳糖和低聚果糖。
实施例11
实施例11,同实施例6,不同之处仅在于,膳食纤维包括质量比2:1的低聚半乳糖和低聚果糖。
实施例12
实施例12,同实施例6,不同之处仅在于,膳食纤维包括质量比4:1的低聚半乳糖和低聚果糖。
对比例1-7提供了一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法,具有说明如下:
对比例1
对比例1,同实施例1,不同之处仅在于,将水解乳清蛋白粉等质量替换为富含乳脂肪球膜的浓缩乳清蛋白粉。
对比例2
对比例2,同实施例1,不同之处仅在于,将富含乳脂肪球膜的浓缩乳清蛋白粉等质量替换为水解乳清蛋白粉。
对比例3
对比例3,同实施例1,不同之处仅在于,控制水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的总添加量不变,水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的质量比为1:1.5,即水解乳清蛋白粉44Kg、富含乳脂肪球膜的浓缩乳清蛋白粉66Kg。
对比例4
对比例4,同实施例1,不同之处仅在于,控制水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的总添加量不变,水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的质量比为3:1,即水解乳清蛋白粉82.5Kg、富含乳脂肪球膜的浓缩乳清蛋白粉27.5Kg。
对比例5
对比例5,同实施例1,不同之处仅在于,控制水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的总添加量不变,水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的质量比为1:3,即水解乳清蛋白粉27.5Kg、富含乳脂肪球膜的浓缩乳清蛋白粉82.5Kg。
对比例6
对比例6,同实施例1,不同之处仅在于,膳食纤维仅选用低聚半乳糖。
对比例7
对比例7,同实施例1,不同之处仅在于,膳食纤维仅选用低聚果糖。
喂食实验
喂养建议
注:1平匙奶粉约4.5g。
从医院招募130名15天大的新生儿志愿者,男女各半。入选标准为健康、足月儿(胎龄≥37周)、阴道分娩;经过医学上证明是健康婴儿;无症状和无疾病体征;记录志愿者入组时的生理指标:体重、身长、头围,其中,体重均在3-4Kg范围内;身长均在48-52cm范围内;头围均在33-36cm范围内。
将130名志愿者随机分成13组,每组10名,男女各半。分成实施例1-12组和对照组;实施例1-12组分别喂食实施例1-12中制得的婴儿配方奶粉;对照组进行母乳喂养,喂养至6月龄时,分别对体重、身长和头围指标进行检测,结果显示体重均落在8-10.5Kg范围内;身长均在69-74cm范围内;头围均在39-45.5cm范围内,所有志愿者生长指标正常。
促进消化吸收性能实验
1、取130只小鼠,予以不规则喂食和夹尾刺激双因素法造模,即双日正常进食,逢单日禁食不禁水,连续2周后,继续以上喂养方法的同时,用长海绵钳夹大鼠尾巴远端1/3处,以不破皮为度,以激怒小鼠,每次夹尾刺激20min,每隔3h刺激1次,3次/天,连续刺激1周,所有小鼠均出现饮食不佳,大便稀溏,气味臭秽刺鼻,性情暴躁,易被激怒等症状,表示造模成功。
2、测试。将消化不良的小鼠随机分成13组,每组10只,以4.5g实施例6、8-12及对比例1-7中制得的配方奶粉样品用30ml温开水溶解的比例,将配方奶粉样品溶解后,采用小鼠自由进食的方式用于小鼠喂养,喂养4周,记录喂养期间各组小鼠的情绪表现、排便表现以及喂养结束时的平均体重日增加量,记录结果如下表1所示。
为了准确记录每一组小鼠的进食量,所有小鼠均单笼饲养于不锈钢笼内,并配以塑料水瓶和不锈钢吸水管。
情绪表现即情绪由易怒转变为稳定时的喂养天数;排便表现即粪便状态由稀溏便转变为正常粪便时的喂养天数;
平均体重日增加量=(测试末体重量-测试开始体重量)/测试天数。
实验组 | 情绪表现 | 排便表现 | 体重日增加量/g |
实施例6组 | 9 | 15 | 7.24 |
实施例8组 | 10 | 15 | 7.19 |
实施例9组 | 9 | 17 | 6.78 |
实施例10组 | 11 | 16 | 6.89 |
实施例11组 | 8 | 12 | 7.85 |
实施例12组 | 10 | 14 | 7.04 |
对比例1组 | 13 | 18 | 5.83 |
对比例2组 | 14 | 18 | 6.07 |
对比例3组 | 11 | 16 | 6.64 |
对比例4组 | 13 | 16 | 6.32 |
对比例5组 | 14 | 16 | 6.15 |
对比例6组 | 12 | 17 | 5.73 |
对比例7组 | 12 | 18 | 5.69 |
结合上述表1显示数据可知:
本申请实施例6、8-12提供的一种促进消化吸收的肠道型婴儿配方奶粉较对比例1-7中提供的一种促进消化吸收的肠道型婴儿配方奶粉,能够起到明显的帮助改善肠道环境,促进消化吸收的效果。
本具体实施例仅仅是对本申请的解释,其并不是对本申请的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本申请的权利要求范围内都受到专利法的保护。
Claims (9)
1.一种促进消化吸收的肠道型婴儿配方奶粉,其特征在于,包括以下重量份的原料:a2-β酪蛋白型生牛乳1500-2100份、脱盐乳清粉300-500份、OPO结构脂100-150份、水解乳清蛋白粉40-70份、富含乳脂肪球膜的浓缩乳清蛋白粉40-70份、乳糖40-60份、膳食纤维40-60份、矿物质20-30份、维生素12-18份、花生四烯酸粉末5-10份、二十二碳六烯酸粉末2-5份、牛磺酸0.1-1份、动物双歧杆菌Bb-12 0.1-1份、叶黄素0.01-0.1份。
2.根据权利要求1所述的促进消化吸收的肠道型婴儿配方奶粉,其特征在于,包括以下重量份的原料:a2-β酪蛋白型生牛乳1600-2000份、脱盐乳清粉350-450份、OPO结构脂110-140份、水解乳清蛋白粉50-60份、富含乳脂肪球膜的浓缩乳清蛋白粉50-60份、乳糖45-55份、膳食纤维45-55份、矿物质22-28份、维生素13-17份、花生四烯酸粉末6-9份、二十二碳六烯酸粉末3-4份、牛磺酸0.3-0.8份、动物双歧杆菌Bb-12 0.3-0.8份、叶黄素0.03-0.08份。
3.根据权利要求1所述的促进消化吸收的肠道型婴儿配方奶粉,其特征在于,包括以下重量份的原料:a2-β酪蛋白型生牛乳1800份、脱盐乳清粉400份、OPO结构脂125份、水解乳清蛋白粉55份、富含乳脂肪球膜的浓缩乳清蛋白粉55份、乳糖50份、膳食纤维50份、矿物质25份、维生素15份、花生四烯酸粉末7.5份、二十二碳六烯酸粉末3.5份、牛磺酸0.5份、动物双歧杆菌Bb-12 0.5份、叶黄素0.05份。
4.根据权利要求1所述的促进消化吸收的肠道型婴儿配方奶粉,其特征在于,所述水解乳清蛋白粉和富含乳脂肪球膜的浓缩乳清蛋白粉的质量比为1-1.5:1。
5.根据权利要求1所述的促进消化吸收的肠道型婴儿配方奶粉,其特征在于,所述膳食纤维包括质量比1.5-4:1的低聚半乳糖和低聚果糖。
6.根据权利要求1所述的促进消化吸收的肠道型婴儿配方奶粉,其特征在于,所述矿物质包括磷酸三钙、柠檬酸钾、氯化钠、氯化钾、硫酸镁、碳酸钙、碘酸钾、硫酸铜、硫酸亚铁、硫酸锌、亚硒酸钠和硫酸锰。
7.根据权利要求1所述的促进消化吸收的肠道型婴儿配方奶粉,其特征在于,所述维生素L-抗坏血酸、氯化胆碱、肌醇、DL-α-醋酸生育酚、盐酸吡哆醇、胆钙化醇、醋酸视黄酯、烟酰胺、D-泛酸钙、叶酸、D-生物素、植物甲萘醌、核黄素、盐酸硫胺素和氰钴胺。
8.一种权利要求1-7任一项所述的促进消化吸收的肠道型婴儿配方奶粉的制备方法,其特征在于,包括以下制备步骤:
S1、验收原辅料后,将a2-β酪蛋白型生牛乳进行净乳及巴氏杀菌;
S2、以a2-β酪蛋白型生牛乳为基料,将OPO结构脂、膳食纤维加入到a2-β酪蛋白型生牛乳中,加入矿物质进行湿混配料,均质后,加入维生素配料,杀菌浓缩、喷雾干燥、冷却获得半成品;
S3、将剩余原辅料进行杀菌后与步骤S2中的半成品进行干混,混合均匀后包装即得所需婴儿配方奶粉。
9.根据权利要求8所述的促进消化吸收的肠道型婴儿配方奶粉的制备方法,其特征在于,所述步骤S2中矿物质和维生素加入前需分别进行预溶解,溶解水温均为40-45℃,溶解时间为1-3min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310222688.7A CN116349734A (zh) | 2023-03-09 | 2023-03-09 | 一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310222688.7A CN116349734A (zh) | 2023-03-09 | 2023-03-09 | 一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116349734A true CN116349734A (zh) | 2023-06-30 |
Family
ID=86911590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310222688.7A Pending CN116349734A (zh) | 2023-03-09 | 2023-03-09 | 一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116349734A (zh) |
-
2023
- 2023-03-09 CN CN202310222688.7A patent/CN116349734A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2026791B1 (en) | Maternal supplement | |
MX2010012905A (es) | Probioticos para mejorar la microbiota intestinal. | |
CN104206539A (zh) | 一种益生菌婴幼儿奶粉 | |
JP5864676B2 (ja) | 貧血の予防又は治療用組成物 | |
MX2011000737A (es) | Probioticos para aumentar la secrecion de iga en infantes nacidos a traves de operacion cesarea. | |
CN109169916A (zh) | 一种产妇营养品及其生产工艺 | |
CN106035674A (zh) | 添加益生元的早产儿与低出生体重儿配方奶粉和制备方法 | |
CN109156535A (zh) | 一种孕妇营养品及其生产工艺 | |
CN112385843A (zh) | 含复合益生元的均衡营养粉及其制备方法 | |
CN107467193B (zh) | 一种以羊奶为基础的粉剂全营养特殊医学用途配方食品及其制备方法 | |
CN111491638A (zh) | 用于在婴儿和幼儿中促进消化能力的包含至少一种n-乙酰化低聚糖和至少一种岩藻糖基化低聚糖的组合物 | |
KR20040019092A (ko) | 박테리아 과성장 예방용 영양 조성물 | |
CN107927198A (zh) | 一种用于早产儿饮用奶粉及其制备方法 | |
CN108432880A (zh) | 一种适用于备孕期女士的配方奶粉及其制备方法 | |
CN105685904B (zh) | 一种产妇分娩用果冻及其制备方法 | |
CN116349734A (zh) | 一种促进消化吸收的肠道型婴儿配方奶粉及其制备方法 | |
CN106615149A (zh) | 含有活性双歧杆菌和抗性糊精的婴儿配方奶粉及制备方法 | |
CN117598475A (zh) | 一种成人特殊医学用途全营养配方食品及其制备方法 | |
CN109645466A (zh) | 一种针对儿童肿瘤患者食用的组合物 | |
CN116548608B (zh) | 一种儿童全营养配方粉及其制备方法和应用 | |
CN114668044A (zh) | 一种婴幼儿配方绵羊奶粉 | |
EP2858653A1 (en) | Bovine colostrum as minimal enteral nutrition for preterm infants | |
CN112806577B (zh) | 产丁酸的益生元益生菌增效组合 | |
CN117084403A (zh) | 一种营养组合物及其制备方法和用途 | |
CN116172191A (zh) | 营养组合物及其在制备抗炎产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |